10-Q: Aptevo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Aptevo Therapeutics reports a net loss of $17.8 million for the nine months ended September 30, 2024, and discusses ongoing clinical trials and recent financing activities.

Summary

• Aptevo Therapeutics, a clinical-stage biotechnology company, reported a net loss of $17.8 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents totaled $7.8 million as of September 30, 2024.
• Research and development expenses decreased to $10.5 million for the nine months ended September 30, 2024, compared to $13.5 million for the same period in 2023.
• General and administrative expenses also decreased to $7.7 million for the nine months ended September 30, 2024, from $9.0 million in the prior year period.
• The company completed multiple public offerings and registered direct offerings of common stock and warrants, raising net proceeds of $11.8 million during the nine months ended September 30, 2024.
• Aptevo is actively developing immuno-oncology candidates, including mipletamig and ALG.APV-527, which are currently in clinical trials.
• The company has an accumulated deficit of $241.3 million as of September 30, 2024.
• Net cash used in operating activities was $18.0 million for the nine months ended September 30, 2024.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses and concerns about the company's ability to continue as a going concern, despite some positive clinical trial data and successful capital raises. The overall sentiment is negative due to the financial instability and high risks.

Positives

• The company successfully raised capital through multiple offerings, providing funds for ongoing operations and clinical trials.
• Aptevo is actively advancing its clinical programs, including mipletamig and ALG.APV-527.
• The company has reduced operating expenses in both research and development and general and administrative areas.
• The Phase 1 trial of ALG.APV-527 showed promising results with 60% of patients achieving stable disease.

Negatives

• Aptevo reported a significant net loss of $17.8 million for the nine months ended September 30, 2024.
• The company has an accumulated deficit of $241.3 million.
• Net cash used in operating activities was $18.0 million for the nine months ended September 30, 2024.
• The company's cash reserves are relatively low at $7.8 million, raising concerns about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and negative cash flows.
• Aptevo will need to raise additional funds to support its operating and capital needs.
• The company faces significant challenges and uncertainties, including potential delays in clinical trials and difficulties in raising capital.
• There is a risk of delisting from the Nasdaq Capital Market if the company does not maintain compliance with listing requirements.
• The company is subject to risks associated with clinical trials, including potential delays, negative results, and adverse events.
• The company relies on third parties for manufacturing and clinical trials, which introduces risks related to their performance and compliance.
• The company's future income depends, in part, on the ability of Medexus to successfully further develop, market and commercialize IXINITY, resulting in milestone payments to the Company by Medexus.
• The company is subject to macroeconomic conditions, including rising and fluctuating inflation, interest rates, market volatility, economic uncertainty, and supply chain constraints.

Future Outlook

The company anticipates continuing to incur significant operating losses for the next several years as it continues to execute its development strategy. They will require substantial additional funds to continue their development programs and to fulfill their planned operating goals.

Management Comments

• Management has concluded that a substantial doubt is deemed to exist concerning the company's ability to continue as a going concern through August 2025.
• Management believes that the company will need to raise additional funds to support its operating and capital needs.

Industry Context

The biotechnology industry is highly competitive, and Aptevo faces competition from numerous companies developing similar therapies. The company's success depends on its ability to develop and commercialize its product candidates effectively and efficiently.

Comparison to Industry Standards

• The company's cash burn rate is high compared to other companies of similar size and stage, indicating a need for significant additional funding.
• The company's reliance on third-party manufacturers and CROs is common in the industry, but introduces risks that need to be carefully managed.
• The company's clinical trial results for ALG.APV-527 are promising, but further data is needed to assess its potential for commercial success.
• The company's multiple capital raises in 2024 are indicative of the need for ongoing funding in the biotechnology sector, but also highlight the company's financial challenges.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's financial challenges.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers and partners may be concerned about the company's ability to continue its operations and fulfill its obligations.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company will continue to advance its clinical programs, including mipletamig and ALG.APV-527.
• The company will seek additional funding to support its operations and development activities.
• The company will continue to monitor and manage its financial resources and operating expenses.
• The company will work to maintain compliance with Nasdaq listing requirements.

Key Dates

Keywords

Aptevo Therapeutics, immuno-oncology, clinical trials, mipletamig, ALG.APV-527, biotechnology, ADAPTIR, ADAPTIR-FLEX, warrants, public offering, reverse stock split, net loss, research and development, financial results